mivacurium

Trade name: mivacron

Small moleculeapproved

Approved

Jan 22, 1992

Mivacurium chloride (Mivacron) is a new benzylisoquinolinium choline-like diester neuromuscular blocking drug with an onset of action at equipotent doses that is comparable to atracurium and vecuronium but slower than succinylcholine. MIVACRON (a mixture of three stereoisomers) binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine. MIVACRON is a short-acting neuromuscular blocking agent indicated for inpatients and outpatients, as an adjunct to general anesthesia, to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. — NCATS

Clinical trial activity

8 trials · 10 clinical orgs · 5 marketing orgs

Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
3

Earliest trial started Jun 1, 2011 (NCT01427985)

Timeline

1990s

  1. Jan 22, 1992

    Burroughs Wellcome — Earliest FDA Approval

  2. Jan 22, 1992

    Burroughs Wellcome — NDA Organization

  3. Jan 22, 1992

    AbbVie — NDA Secondary Org

2000s

  1. Apr 30, 2009

    Rising Pharmaceuticals — Marketing Organization

  2. Apr 30, 2009

    Mylan — Marketing Organization

2010s

  1. Jan 1, 2013

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2014

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Oct 12, 2021

    Woodward — Marketing Organization

Indications

Mechanism of action

Approval history

  • approvedPriority reviewJan 22, 1992

Chemistry & pharmacology

Loading structure…

SMILES

COc1cc2c(cc1OC)[C@@H](Cc1cc(OC)c(OC)c(OC)c1)[N+](C)(CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]1(C)CCc3cc(OC)c(OC)cc3[C@H]1Cc1cc(OC)c(OC)c(OC)c1)CC2
Mol. weight
1029.28 g/mol
Chirality
Racemic Mixture
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Discontinued

Oral

No

Parenteral

Yes

Topical

No

Sources

Also known as

  • bw b1090u
  • bw-b1090u
  • bw-b 1090u
  • bw-b-1090u
  • bwb109ou
  • bwb109ou
  • bw-b109ou
  • bw-b109ou
  • bw-b109ou dichloride
  • bw-b109ou dichloride
  • mivacron
  • mivacron
  • mivacron
  • mivacron
  • mivacron
  • mivacurium
  • mivacurium
  • mivacurium
  • mivacurium
  • mivacurium
  • mivacurium
  • mivacurium
  • mivacurium
  • mivacurium
  • mivacurium
  • mivacurium chloride
  • mivacurium chloride
  • mivacurium chloride
  • mivacurium chloride
  • mivacurium chloride

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06072534N/ASep 1, 2023Al Azhar University
NCT02664142N/AJun 1, 2015University of Ostrava
NCT02473601Phase 2Oct 1, 2014Jiangsu Nhwa Pharmaceutical Co., Ltd., Jiao Tong University, People's Liberation Army of China
NCT01966484N/AOct 1, 2013Johannes Gutenburg University
NCT01906528Phase 1Mar 1, 2013Osaka University, University of California, San Francisco
NCT01631149Phase 4Jun 1, 2012Leiden University
NCT02117401Phase 4Jan 1, 2012Jiangsu Nhwa Pharmaceutical Co., Ltd.
NCT01427985Phase 4Jun 1, 2011University of Ulm
Showing 8 of 8 trials
Page 1 / 1

Organizations

Research & Development (10)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Jiangsu Nhwa Pharmaceutical Co., Ltd.For profit2122012
Al Azhar UniversityAcademic/Hospital1112023
Jiao Tong UniversityAcademic/Hospital1012014
Johannes Gutenburg UniversityAcademic/Hospital1112013
Leiden UniversityAcademic/Hospital1112012
Osaka UniversityAcademic/Hospital1012013
People's Liberation Army of ChinaGovernment1112014
University of California, San FranciscoAcademic/Hospital1112013
University of OstravaAcademic/Hospital1112015
University of UlmAcademic/Hospital1112011
10 organizations
Page 1 / 1

Marketing (6)

OrganizationOrg typeRelationshipDate
AbbVieFor profitNDA2Jan 22, 1992
Burroughs WellcomeFor profitNDAJan 22, 1992
MylanFor profitMKTGApr 30, 2009
Rising PharmaceuticalsFor profitSYNApr 30, 2009
Rising PharmaceuticalsFor profitMKTGApr 30, 2009
WoodwardFor profitMKTGOct 12, 2021